查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1959978

耐火濾泡性淋巴瘤診斷市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、方法、最終用戶、地區和競爭對手分類，2021-2031年

Refractory Follicular Lymphoma Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Method, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球難治性濾泡性淋巴瘤診斷市場預計將從 2025 年的 4.9 億美元成長到 2031 年的 6.9 億美元，複合年成長率為 5.87%。

該領域涵蓋專門的診斷測試和影像解決方案，旨在檢測和表徵復發性或難治性濾泡性淋巴瘤。組織切片檢查、免疫組化和基因組分析等關鍵工具使臨床醫生能夠確認疾病抗藥性並識別侵襲性亞型的轉化。市場成長的主要驅動力是全球骨髓惡性腫瘤發生率的上升以及對基於生物標記的精準醫療日益成長的需求。根據2024年白血病和淋巴瘤協會（LLS）的數據，濾泡性淋巴瘤約佔所有非何傑金氏淋巴瘤診斷的22%，這意味著有大量患者需要長期疾病監測。

市場概覽
預測期 2027-2031
市場規模：2025年 4.9億美元
市場規模：2031年 6.9億美元
複合年成長率：2026-2031年 5.87%
成長最快的細分市場 試劑盒和耗材
最大的市場 北美洲

儘管臨床需求強勁，但由於先進診斷技術成本高昂，市場面臨許多障礙。分子檢測和次世代定序的高昂費用往往受到醫保報銷的限制，這阻礙了其廣泛應用，並限制了資源匱乏的醫療環境下的市場擴張。

市場促進因素

對微量殘存疾病（MRD）監測日益成長的需求正在重塑全球難治性濾泡性淋巴瘤診斷市場，實現高靈敏度、非侵入性的監測。臨床醫生正轉向使用液態生物檢體技術檢測循環腫瘤DNA（ctDNA），在臨床症狀出現之前識別深度分子緩解或早期復發。次世代定序檢測技術的快速普及也印證了這一趨勢，該技術可用於追蹤克隆演進。例如，Adaptive Biotechnologies在其2025年2月的財報中宣布，其clonoSEQ檢測量達到76,105例，同比成長35%，這反映了MRD評估在淋巴系統惡性腫瘤臨床應用中的廣泛普及。

此外，基於生物標記的精準醫療的擴展正在推動市場需求，因為在新型雙特異性抗體療法中，可靠的診斷分析對於指南治療方案的選擇至關重要。伴隨診斷對於標靶治療的核准至關重要，其旨在確認抗原表現並監測難治性患者群體的長期療效。根據基因泰克公司2024年12月發布的關於Columvi和Lunsumio的最新資訊，接受mosnetuzumab治療並達到完全緩解的患者中，約64.0%在45個月時仍無惡化生存期，這凸顯了持續監測策略的必要性。此外，治療效果的改善也延長了檢測的適用期。 OncologyNewsCentral在2025年報告稱， Tafasitamab、Lenalidomide和Rituximab聯合治療的中位無惡化生存期期為22.4個月，顯著延長了縱向診斷監測的適用期。

市場挑戰

全球難治性濾泡性淋巴瘤診斷市場的發展受到引入先進診斷技術所帶來的巨大經濟負擔的嚴重限制。諸如次世代定序和分子譜分析等專業工具運作成本高昂，且往往超出標準醫保報銷範圍。因此，在注重成本控制的環境下，醫療機構在申請這些昂貴的檢測時常常面臨行政阻力，迫使他們依賴價格更低但整體性的替代方案。這種經濟障礙限制了複雜診斷技術的應用，減少了檢測數量，並直接限制了市場相關人員的商機。

血液腫瘤領域面臨的巨大經濟壓力進一步加劇了這項挑戰。根據白血病和淋巴瘤協會 (LLS) 2024 年的一項調查，確診淋巴瘤的私人保險患者在開始治療後的短短六個月內，醫療總費用可能超過 13 萬美元（約 1,400 萬日圓）。如此高昂的基本醫療支出迫使醫療系統和支付方仔細審查各項附加費用，這往往導致高價值診斷程序的報銷被拒絕或限制。這種經濟負擔實際上縮小了目標市場，使得相當一部分患者無法獲得先進的檢測解決方案。

市場趨勢

將人工智慧 (AI) 整合到診斷工作流程中，正在提高難治性濾泡性淋巴瘤鑑別診斷的準確性和效率。檢查室正超越傳統的人工審核，採用開放式數位病理生態系統，該系統整合了第三方演算法，用於自動影像分析和亞型分類。這種技術變革透過管理日益複雜的組織評估，降低了診斷差異，並使病理學家能夠在單一介面中無縫部署各種計算工具。根據羅氏公司 2024 年 9 月發布的 AI 驅動型癌症診斷進展公告，該公司已將來自八家新合作夥伴的 20 多種先進 AI 演算法整合到其數位病理軟體中，顯著擴展了臨床醫生用於癌症檢查和診斷的分析能力。

同時，為了因應高風險患者疾病進展的異質性，整合多體學資料進行精準分層正成為關鍵趨勢。診斷研發公司正加強與研究機構的合作，以產生整合臨床病史、基因測序、蛋白質體學和甲基化譜分析的綜合資料集。這種綜合辦法旨在發現新型生物標記物，這些標誌物能夠比單一分析物檢測更準確地預測早期復發，並有助於對進行性病變進行早期療育。根據 Investing.com 2024 年 11 月報道，Tempus 與 IFLI 的合作專注於這種多模態分析，旨在解決約 20% 的濾泡性淋巴瘤患者在接受初始化療免疫治療兩年內出現疾病進行性這一重大未滿足的醫療需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球防火濾泡性淋巴瘤診斷市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 產品類別（設備、套件和耗材）
    • 方法（免疫組織化學（IHC）、原位雜合反應（ISH）、聚合酵素鏈鎖反應（PCR）、其他）
    • 依最終用戶（醫院、診斷中心等）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美防火濾泡性淋巴瘤診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲耐火濾泡性淋巴瘤診斷試劑市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區防火濾泡性淋巴瘤診斷市場的展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲地區耐火濾泡性淋巴瘤診斷市場的展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲抗纖維化濾泡性淋巴瘤診斷市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球耐火濾泡性淋巴瘤診斷市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Roche Diagnostics
  • Abbott
  • Thermo Fisher Scientific
  • Agilent Technologies
  • QIAGEN
  • Bio-Rad
  • Danaher
  • Illumina
  • PerkinElmer
  • Cell Signaling Technology

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 26771

The Global Refractory Follicular Lymphoma Diagnostics Market is projected to expand from USD 0.49 Billion in 2025 to USD 0.69 Billion by 2031, registering a CAGR of 5.87%. This sector comprises specialized diagnostic testing and imaging solutions designed to detect and characterize follicular lymphoma that has relapsed or failed to respond to treatment. Essential tools such as tissue biopsies, immunohistochemistry, and genomic profiling enable clinicians to confirm disease resistance and identify transformation into aggressive subtypes. Market growth is fundamentally driven by the rising global prevalence of hematologic malignancies and the increasing demand for biomarker-driven precision medicine. Data from the Leukemia & Lymphoma Society in 2024 indicates that follicular lymphoma accounted for an estimated 22% of all non-Hodgkin lymphoma diagnoses, highlighting the significant volume of patients requiring long-term disease monitoring.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 0.49 Billion
Market Size 2031USD 0.69 Billion
CAGR 2026-20315.87%
Fastest Growing SegmentKits & Consumables
Largest MarketNorth America

Despite robust clinical demand, the market faces significant hurdles regarding the high financial burden of advanced diagnostic technologies. The elevated costs associated with molecular testing and next-generation sequencing frequently encounter reimbursement limitations, which hinders widespread accessibility and restricts market expansion in healthcare environments with limited resources.

Market Driver

The increasing necessity for Minimal Residual Disease (MRD) monitoring is reshaping the Global Refractory Follicular Lymphoma Diagnostics Market by facilitating highly sensitive, non-invasive surveillance. Clinicians are shifting toward liquid biopsy technologies to detect circulating tumor DNA (ctDNA), permitting the identification of deep molecular remission or early relapse before clinical symptoms appear. This trend is demonstrated by the rapid adoption of next-generation sequencing assays for tracking clonal evolution; for instance, Adaptive Biotechnologies reported in their February 2025 financial results that clonoSEQ test volumes rose 35% year-over-year to 76,105 tests, reflecting the surging clinical integration of MRD assessment in lymphoid malignancies.

Furthermore, the expansion of biomarker-based precision medicine is propelling market demand, as novel bispecific antibodies require robust diagnostic profiling to guide therapeutic selection. The approval of targeted agents necessitates companion diagnostics to confirm antigen expression and monitor long-term efficacy in refractory populations. According to a December 2024 update from Genentech regarding Columvi and Lunsumio, nearly 64.0% of patients achieving a complete response to mosunetuzumab were alive without disease progression at 45 months, emphasizing the need for durable monitoring strategies. Additionally, improved therapeutic outcomes extend the testing window; OncologyNewsCentral reported in 2025 that the combination of tafasitamab, lenalidomide, and rituximab demonstrated a median progression-free survival of 22.4 months, significantly broadening the timeframe for longitudinal diagnostic oversight.

Market Challenge

The growth of the Global Refractory Follicular Lymphoma Diagnostics Market is significantly hampered by the substantial financial burden associated with deploying advanced diagnostic technologies. Specialized tools such as next-generation sequencing and molecular profiling incur high operational costs that frequently exceed the coverage limits of standard reimbursement policies. Consequently, healthcare providers in cost-sensitive environments often face administrative resistance when ordering these premium tests, forcing them to rely on less expensive but less comprehensive alternatives. This economic barrier limits the widespread adoption of precision diagnostics, thereby reducing the volume of tests performed and directly constraining revenue opportunities for market players.

This challenge is further exacerbated by the intense economic pressure within the hematologic oncology sector. Research findings from the Leukemia & Lymphoma Society in 2024 indicated that privately insured patients diagnosed with lymphoma can incur total healthcare costs exceeding $130,000 within just the first six months of care. Such elevated baseline expenditures compel healthcare systems and payers to scrutinize all ancillary costs, often resulting in the rejection or limitation of claims for high-value diagnostic procedures. This financial toxicity effectively shrinks the addressable market by rendering advanced testing solutions inaccessible to a significant portion of the patient population.

Market Trends

The Integration of Artificial Intelligence in Diagnostic Workflows is enhancing the precision and efficiency of characterizing refractory follicular lymphoma. Laboratories are increasingly transitioning beyond traditional manual reviews by adopting open digital pathology ecosystems that incorporate third-party algorithms for automated image analysis and sub-typing. This technological shift manages the increasing complexity of tissue evaluation, allowing pathologists to seamlessly deploy varied computational tools within a single interface to reduce diagnostic variability. As noted by Roche in September 2024 regarding their advancement of AI-driven cancer diagnostics, the company integrated more than 20 advanced artificial intelligence algorithms from eight new collaborators into its digital pathology software, significantly broadening the analytical capabilities available to clinicians for cancer research and diagnosis.

Concurrently, the Convergence of Multi-Omics Data for Precision Stratification is emerging as a vital trend to address the heterogeneity of disease progression in high-risk patients. Diagnostic developers are increasingly partnering with research institutions to generate comprehensive datasets that combine clinical history with genomic sequencing, proteomics, and methylation profiling. This holistic approach aims to uncover novel biomarkers that can predict early relapse more accurately than single-analyte tests, facilitating earlier intervention for aggressive transformations. According to Investing.com in November 2024, a partnership between Tempus and IFLI focuses on this multi-modal analysis to address the critical unmet need where about 20% of follicular lymphoma patients experience progressive disease within two years of initial chemoimmunotherapy.

Key Market Players

  • Roche Diagnostics
  • Abbott
  • Thermo Fisher Scientific
  • Agilent Technologies
  • QIAGEN
  • Bio-Rad
  • Danaher
  • Illumina
  • PerkinElmer
  • Cell Signaling Technology

Report Scope

In this report, the Global Refractory Follicular Lymphoma Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Refractory Follicular Lymphoma Diagnostics Market, By Product

  • Instruments
  • Kits & Consumables

Refractory Follicular Lymphoma Diagnostics Market, By Method

  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Polymerase Chain Reaction (PCR)
  • Others

Refractory Follicular Lymphoma Diagnostics Market, By End User

  • Hospitals
  • Diagnostic Centers
  • Others

Refractory Follicular Lymphoma Diagnostics Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Refractory Follicular Lymphoma Diagnostics Market.

Available Customizations:

Global Refractory Follicular Lymphoma Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Refractory Follicular Lymphoma Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Instruments, Kits & Consumables)
    • 5.2.2. By Method (Immunohistochemistry (IHC), In Situ Hybridization (ISH), Polymerase Chain Reaction (PCR), Others)
    • 5.2.3. By End User (Hospitals, Diagnostic Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Refractory Follicular Lymphoma Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Method
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Method
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Method
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Method
        • 6.3.3.2.3. By End User

7. Europe Refractory Follicular Lymphoma Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Method
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By End User
    • 7.3.2. France Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Method
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Method
        • 7.3.5.2.3. By End User

8. Asia Pacific Refractory Follicular Lymphoma Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Method
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By End User
    • 8.3.2. India Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Method
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Method
        • 8.3.5.2.3. By End User

9. Middle East & Africa Refractory Follicular Lymphoma Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Method
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By End User

10. South America Refractory Follicular Lymphoma Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Method
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Method
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Method
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Refractory Follicular Lymphoma Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Method
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Refractory Follicular Lymphoma Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Roche Diagnostics
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott
  • 15.3. Thermo Fisher Scientific
  • 15.4. Agilent Technologies
  • 15.5. QIAGEN
  • 15.6. Bio-Rad
  • 15.7. Danaher
  • 15.8. Illumina
  • 15.9. PerkinElmer
  • 15.10. Cell Signaling Technology

16. Strategic Recommendations

17. About Us & Disclaimer